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Background: Appropriate ICD programming is the key to prevent inappropriate shock de-
livery, that is closely associated to a negative patients’ outcome.
Methods: Review of the literature on ICD therapy to generate ICD programmings that can be
applied to the broad population of ICD and CRT-D carriers.
Results: Arrhythmia detection should occur with a detection time ranging 900e1200 in the VF
zone, and 1500e6000 in the VT zone. Discriminator should be applied at least up to 200 bpm.
ATP therapy is applied to all VTs up to 250 bpm, with a success rate of 70%. Inappropriate
shocks should occur in <3.6% of patients.
Conclusion: Tailored ICD programming can be achieved following evidence from large ICD
trials. Pre-defined settings that are saved on the programmer and that can be uploaded at
device implantation help to ensure optimal programming and to avoid random errors.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction
Automatic Implantable Cardioverter-Defibrillators (ICD) are
the cornerstone in the prevention of sudden death both in
patients at risk of life-threatening ventricular arrhythmias
with or without heart failure (primary prevention), and in
patients rescued from non-tolerated ventricular tachycardia
(VT) or ventricular fibrillation (secondary prevention).1e6 ICD
efficacy is largely proven in several randomized controlled
studies,1e6 however concern has arisen about the potentially
harmful effect of shock therapy being delivered to terminate
ventricular arrhythmias (appropriate therapy delivery), or
inappropriately delivered because of misclassified supraven-
tricular arrhythmias (SVT), self-terminating non-sustained
ventricular tachycardia (NSVT), and oversensing of both car-
diac and non-cardiac signals.7 Therapy delivered for causes
other than VT/VF is termed “inappropriate”, and has beenla-Malpighi, University o
2013, Cardiological Sociereported to occur in up to 17% of patients of heart failure pa-
tients.7 Shock delivery, whether appropriate or inappropriate,
has been reported to negatively impact patient survival, being
closely associated to progressive pump failure.7 In the recently
published MADIT-RIT study, inappropriate delivery of anti-
tachycardia pacing (ATP) because of SVT was found associ-
ated to increased mortality, although this finding has no
pathophysiologically valid explanation.8,9 In several studies
the chances of therapy delivery was higher in the sickest pa-
tients with multiple co-morbidities1,2,4 so it is speculative e
but very likely e that therapy delivery is simply a marker of a
more severe clinical scenario, the association to mortality
thus being almost ineluctable.
This review will summarize the principles that may assist
clinicians in defining ICD settings that may be suitable to the
vast majority of patients as a generic framework to reduce
inappropriate therapydeliverywhilemaintaining theefficacy tof Bologna, Via Massarenti 9, 40138 Bologna, Italy. Fax: þ39 (0) 51
ty of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 8es 1 0 0 S89detect and terminateVTandVF, and that canbeused toprovide
an individualized programming for any specific patient.
In this review we will not consider device programming
based on a primary or secondary prevention of sudden death
setting. The major difference among these two patient pop-
ulations is the burden of ventricular arrhythmia and the time
of arrhythmia onset after ICD implantation, whereas the type
of arrhythmia being detected and the efficacy of the therapy
being delivered is similar.10 Indeed, these latter are related to
the underlying disease and to the extent of myocardial dam-
age, which are quite homogeneous among each specific dis-
ease etiology.
Device programming based on disease etiology is focused
on the occurrence of VT that is ATP-terminable: a low chance
favors a single, fast arrhythmia zone (VF), whereas a high
chance favors a VF þ VT zone.
The goals of ICD programming are:
- detect high rate NSVT, as they are predictive of ICD
discharge for life-threatening arrhythmias and all-cause
mortality, and should prompt medical interventions to
improve patients’ outcome11
- avoid unnecessary treatment of NSVT by delaying ICD
intervention as tolerated by the patient
- discriminate SVTs
- terminate sustained VT and VF while minimizing shock
therapy
- monitor AF, SVTs, and slow VTs for stroke prevention
management, ablative and/or drug therapy
- provide alert on technical (lead integrity and device) and
patient-related (atrialfibrillation,heart failure)medical issuesFig. 1 e Example of pre-defined settings suitable for the majori
SAVE function (Medtronic and NayaMed). Tailoring for individu
minor changes. A similar function is also available in BiotronikICD programming is a comprehensive process that is based
on the patient’s clinical history and encompasses:
- Choice of the device type
- Arrhythmia detection:ty of I
alized
and SZones setting
Detection duration of each programmed zone
SVT discrimination- Termination of ventricular arrhythmias
- Monitor zone programming
- Device and clinical alerts
For the purpose of this review, the choice of device typewill
be discussed at the end, by the light of the observations that
are relevant to this decision-making step.2. Arrhythmia detection
Programming the features to achieve automatic arrhythmia
diagnosis by the implanted device requires clinical as well
technical knowledge, and may be hindered by several factors
such as the frequent changes of the parameters presentation
format across different device releases and different manu-
facturers, mismatch of the shipment programming compared
to evidence stemming from clinical studies, shortage of time
and multi-tasking during the clinical activity. Individualized
programming is often not achieved in clinical practice, and
this has a negative impact on patient outcome.
To avoid random errors in the set-up of ICD programming,
we have found extremely helpful to save pre-defined custom-CD and CRT-D patients, to be uploaded by the GET &
patient programming can be achieved with only
t Jude Medical devices.
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i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 8es 1 0 0S90made settings in the programmer, that can suit a vastmajority
of patients and that are used to reach a refined, tailored setting
for very specific patients with only a few changes.
This function is available for recent device releases in
Biotronik, Medtronic, NayaMed, and St Jude Medical devices,
and can be loaded after device interrogation (Fig. 1).
2.1. Zones setting
Whatever the device chosen (single or dual chamber, CRT-D)
the programming should be guided by the clinical knowl-
edge of the patient’s history. The key aspect is whether a pa-
tient can benefit from a “VF zone only” setting, or is eligible for
a “VF zone þ VT zone” programming.
Nowadays ATP delivery has become possible before and/or
during capacitor charging, so a setting as “VF zone  200 bpm”
seems a simple and effective programming. Labeling an
arrhythmia zone as “VF” is crucial, as only Medtronic and
NayaMed devices can discriminate SVT with fast ventricular
rate in the VF zone: any SVT entering such a zone would be
treated as VF with other manufacturers. Young patients, who
can achieve very fast atrial rates or have SVTs with fast con-
duction to the ventricles, are at the highest risk of inappropriate
shocks, especially when a subcutaneous ICD is considered.
The impact of VT zone programming on mortality is un-
clear. A high cut-off rate for VT/VF detection as 200 bpm or
even 220 bpm has proved safe and capable to reduce inap-
propriate therapy delivery compared to shipment program-
ming, but has to be traded off with a potentially harmful
under-detection of monomorphic VT in the 170e220 bpm
range.8,12 The tolerance of VT in patients with heart failure or
low EF is unknown a priori, and, although anedoctically
tolerated, is in general poor. Indeed, in the AVID trial the
coexistence of VT slower than 180 bpm and heart failure
identified a subgroup of VT patients at higher mortality risk.13
In the AVID trial patients with symptomatic VT or hemody-
namically stable monomorphic VT and low EF had a poorer
prognosis than patients presenting with VF, underlying that
VT slower than 180 bpm is not a benign arrhythmia, and
suggests the presence of a cardiac substrate at risk of both
SCD and pump failure.14 Also in primary prevention patients
therapy delivery for either VT or VF was associated to
increased arrhythmic and heart failure-related mortality; VTs
faster than 180 bpmwere associated to an only slightly higher
mortality rate compared to slower VTs.8,15 Moreover, the
MADIT-RIT study was not powered to test the difference of a
single zone programming against a VF þ VT zone with pro-
longed detection, as proven effective in the PREPARE and in
the RELEVANT studies,16,17 so it seems clinically appropriate
to use a VF þ VT zone with long detection times for the pa-
tients’ safety.
Based on the fact that about 50% of clinical arrhythmias
had a rate slower than 200 bpm in patients with structural
heart disease and both primary and secondary indication to
ICD therapy,10 we consider feasible an approach to program-
ming that merges the evidences from all available studies, as
summarized in Table 1 and Fig. 2:
- patients with a primary arrhythmia or ion channel disease
in the absence of structural heart disease should have a
Fig. 2 e Suggested programming of Detection in Medtronic/NayaMed single chamber ICDs, as per Tables 1 and 2
recommendations. Panel A is a “VF Only” setting, panel B is “VF D VT zone”. Note that in these manufactures the cut-off
interval belongs to the slower zone, thus VF is ‡300 ms (200 bpm), and VT is set at 350 ms (171 bpm). Detection is 30/40
intervals, Wavelet discrimination up to 260ms (231 bpm) in the VF zone (light blue shaded area). Onset is set to monitor and
stability OFF. Features to avoid T-Wave oversensing and “noise” are active by shipment. A Monitor zone for symptoms
evaluation or slow arrhythmias detection is available.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 8es 1 0 0 S91single VF zone faster than 200 bpm, sincemonomorphic VT
that is ATP-terminable is not in the clinical scenario. When
SVTs with fast ventricular rate coexist, a setting as
VF  250 bpm þ VT 200e250 bpm allows discrimination of
SVT in this latter range, preserving the sensitivity of VT/VF
detection
- patientswith a substrate prone tomonomorphic VT should
have a VT (170e200 bpm) and a VF zone, both with a long
detection time.
- patients with known monomorphic VTs slower than
170 bpm that cause significant hemodynamic compromise
and are resistant or not amenable to drug/ablation therapy
can benefit from a “dual VT zone” programming
The Detection Rate is the primary determinant of the
arrhythmia being detected.
VF labeling means that no SVT arrhythmia can be
discriminated in that zone (apart Medtronic and NayaMed),
hence therapy will be delivered when the detection time is
reached. It is common practice to consider “true VF” a rhythm
faster than 250 bpm, very unlikely to be ATP-terminable and
usually requiring shock therapy.
A rhythm in the range 200e250 bpm is considered a fast VT
(FVT).Nowadays, the treatment for FVT has been incorporated in
the VF zone, since ATP has been made available either before
or during the capacitor charge, thus obviating the need to
program 3 detection zones. Nowadays, a “lean” ICD pro-
gramming can be achieved with a 2 zones setting that ensures
ATP delivery in the broad VT range and also into the VF zone
(Figs. 2 and 3).
2.2. Detection duration
Arrhythmia detection occurs when a fast rate exceeding the
arrhythmia cut-off rate persists for the programmed detection
time, that can be indicated more commonly as intervals, or
time in seconds.
Detection duration is markedly different across manufac-
turers at shipment programming. This parameter is crucial, as
a long detection time has proven as a very useful intervention
to decrease inappropriate ICD therapy delivery.8,16e18
Reprogramming detection duration from shipment is a
necessary step, as only Medtronic provides a shipment VF
detection as 30/40 intervals (9 s at VF ¼ 200 bpm) stemming
from evidence based on available literature.16e18
Detection can be programmed in intervals or in seconds.
The counters are probabilistic (the arrhythmia is declared
Fig. 3 e Therapy setting for both a “VF Only” (Panel A) and a “VFD VT zone” (Panel A D B) setting. When effective, ATP in
the VF zone automatically switches to ”before charging” to improve device longevity. ATP sequences are based on
published studies 10, 18, 31, 33. In CRT-Ds, biventricular ATP is preferred, especially in ischemic heart disease patients.34
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 8es 1 0 0S92present when a fraction of VT/VF intervals over a pro-
grammed sampling window is reached) around a 70e80%
value, depending on the different manufacturers. This strat-
egy ensures timely detection despite the occurrence of a
signal amplitude drop at high ventricular rate during poly-
morphic VT or VF, potentially causing missed intervals.
It has to be remembered that, unlike other manufacturers,
Medtronic and NayaMed have a consecutive counter in the VT
zone and in the Monitor zone: one beat exceeding the detec-
tion cycle will reset the VT counter to 0, thus delaying the
detection process.
A long detection decreases the chances of an unnecessary
therapy delivery due to NSVT. This was firstly reported in a
mixed ICD population in the PREPARE study: detection pro-
longation as 30/40 intervals for VF held a 43% reduction of
appropriate shocks compared to an 18/24 intervals detection
time.16 Since 2009, 3 studies of a long detection vs a conven-
tional one have been published: the RELEVANT (primary pre-
vention CRT-D patients), the MADIT-RIT (primary prevention
dual chamber and CRT-D patients), the ADVANCE III (mixed
ICD population). In RELEVANT, the long detection duration
(30/40) reduced by 90% the number of treated VT and VF epi-
sodes compared to a 12/16 intervals (VF) and a 16 intervals (VT)
detection.17 In the MADIT-RIT study, detections as 1200 in the
range 200e250 bpm and 6000 in the 170e200 bpm range
decreased ATP delivery by 67% against detection durations as
1 s and 2.500, respectively.8 The ADVANCE III trial demon-
strated a highly significant reduction of both appropriate andinappropriate therapy occurrence bymeans of a 30/40 vs 18/24
intervals detection, at no excess of either syncope or
mortality.18
It has to be noted that in the MADIT-RIT the reduction of
treated VT/VF episodes translated in a significant reduction of
ATP delivery only, but not of shocks for life-threatening long-
lasting arrhythmias.8 On the contrary, the RELEVANT and the
ADVANCE III trial respectively reported a significant and a
nearly significant (p ¼ .06) reduction of appropriate shocks by
a long detection time, at no compromise with mortality or
syncope.17,18 Moreover, the RELEVANT study and the
ADVANCE III study respectively reported a decrease of heart
failure-related and all-cause hospitalizations in the long
detection groups.
Compared to the RELEVANT and the MADIT-RIT, the
ADVANCE III trial results can be generalized to all patients,
primary and secondary prevention, and to all ICD types.
Detection duration in the control arm was longer in the
ADVANCE III (18/24) than in the MADIT-RIT (1 s and 2.500
respectively for VF and VT), which may account for some of
the unwanted effect of ATP therapy delivery on VTs possibly
going to be self-terminating.
In the subcutaneous ICD (SQICD), detection is non-
programmable as 18/24, that means that charge delivery oc-
curs in about 16 s, unlike transvenous ICDs (1800e2100), thus
exposing the patients to some unnecessary therapy delivery
on non-sustained VT, unless delayed detection occurs
because of missed intervals. On the other hand, when a non-
Fig. 4 e Benefit of SVT discrimination in the VT and VF zone added to a long Detection duration. Primary prevention patient
with new-onset heart failure 1 year after ICD implantation. From top to bottom : interval plot, episode EGM, Wavelet
snapshot. The patient was in sinus rhythm with very frequent premature beats (see plots). Panel A is VT at 280 ms treated
by ATP before charging in the VF zone: nomatch with template. Panel B is an SVT (see templatematch and interval stability)
on the border zone 280e290 ms: detection is withheld by Wavelet for 1200, longer than Detection Duration, until self
termination. Long detection alone would have caused inappropriate ATP delivery.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 8es 1 0 0 S93sustained VT is detected and charge delivery is aborted, the
detection is prolonged by 1 s in the next detection; this process
can repeat on consecutive episodes up to a maximum of 5
added seconds, thus leading to a smart detection prolongation
up to 2100.
A long detection duration may also help to prevent inap-
propriate therapy delivery due to SVTs, although an important
role is also played by SVT discriminators (Figs. 2 and 4, Table 2).
Indeed, whereas inappropriate shock delivery was signifi-
cantly reduced in both the RELEVANT and in the ADVANCE III
study, no effect was observed in the MADIT-RIT trial, possibly
owing to the absence of SVT discriminators in the VF zone in
Boston Scientific devices. Indeed, inappropriate ATP delivery
on AF or SVTs inducing VT/VF was hypothesized as a possible
explanation of ATP being associated with increased mortality
in the MADIT-RIT trial.8,9
A long detection is also helpful to decrease inappropriate
shocks due to non-cardiac signals such as noise or lead
insulation defects/fractures, that are observed to have typi-
cally a <2000 duration time.Programming the detection duration based on available
studies is reported in Table 1.
2.3. SVT discrimination
Discriminators have been implemented in the detection pro-
cess in a view to withhold VT therapy delivery on sinus
tachycardia and supraventricular arrhythmias. They cannot
work in the VF zone, with exception for Medtronic and
NayaMed.
Discriminatorsmayhavedifferentapproachesatarrhythmia
discrimination:
- analysis of the interval patterns (onset, stability, atrium to
ventricle relationship)
- morphologic analysis of the EGM entering the arrhythmia
zones
Arrhythmia discrimination is applied at VT detection (VF
also for Medtronic and NayaMed), whereas it is not applied
Table 2 e Suggested programming of Discriminators in clinical practice, as from their performance.20e30
ICD type SVT limit First line discriminator Stability Onset
Medtronic &
NayaMed
Single chamber
Dual/CRT-D
260 ms
260 ms
Wavelet, 70% match
PR logic (þwavelet) (Medtronic
only)
50 ms; keep OFF unless
proven to be helpful based
on EGM recordings
81%, Monitor
Caution if VT/VF are
triggered by sinus
tachycardia or SVTs
St Jude Medical Single chamber VT zone Morphology, 60% match
(60 to 90% in Ellipse)
50 ms, works in 2/3 logic 100 ms, works in 2/3 logic
Dual/CRT-D VT zone Rate branch þ Morphology 50 ms, works in V < A
branch (ANY or ALL logic)
100 ms, works in V ¼ A
branch (ANY or ALL logic)
Boston Scientific Single chamber VT zone Rhythm ID, 94% match
(programmable in Incepta)
20 ms, works with onset 9%, works with stability
Dual/CRT-D VT zone Rhythm match (V/A þ Rhythm
ID)
20ms, works in V Awith
A rate > 170 bpm
Not used
Biotronik Single chamber VT zone Smart Detection available also
in single lead, Single chamber
ICD
Integrated in Smart
Detection: programmable
% of cycle or absolute
value, respectively in
Used only in V¼ A, stable
V and A intervals that
have no monotony:
sudden Onset
Dual/CRT-D VT zone Single chamber and dual
chamber
Confirms VT
Sorin Ela Single chamber VT zone Stability Onset when a stable
rhythm is detected
Dual/CRT-D VT zone PARADþ First step of PARADþ Chamber of origin of fast
rhythms when A/V ¼ 1
Cameron Health Single chamber Conditional
shock zone
Discrimination based on: signal
width, amplitude, stability
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) s 8 8es 1 0 0S94during re-detection (after the first therapy has been delivered)
apart from Medtronic, NayaMed, and Boston Scientific, that
can apply Stability during re-detection. Although some simi-
larities exist, the functioning of discriminators is different
across manufacturers.
A description of discriminators functioning is reported in
the Appendix.2.4. Single-chamber ICD
Dual chamber arrhythmia discrimination is nowadays
possible in a single-lead single-chamber ICD to increase
specificity compared to onset þ stability.19,20 In general,
Morphologic discriminators “stand alone”, without any
further discriminator, have been reported to correctly classify
75e90% of SVTs with a sensitivity for VT around 99%, that is
superior to stability and onset working together. They are to
be used as single discriminators, with the others in “monitor
mode” (passive) where available, so that they can be turned
ON only when proven to add significant value to arrhythmia
discrimination.21
In the single study reporting a head to head comparison,
Medtronic wavelet was observed as superior to Boston Sci-
entific Rhythm ID (old release) in discriminating SVTs, at no
compromise with VT detection.22
The reliability of detection with subcutaneous ICDs is
actually suboptimal, with 13% of patients receiving inappro-
priate shocks; the use of a Conditional Shock Zone dramatically
decreases inappropriate shocks due to SVTs.23 Technological
advancement of the SQICD will most likely lead to consistent
improvements in future releases. A clinical study is ongoing to
evaluate the performance of transvenous against subcutane-
ous ICD discrimination.242.5. Dual chamber ICD and CRT-D
A slightly superior accuracy in arrhythmia classification has
been reported with dual chamber ICDs, but this has never
translated into a decrease of inappropriate therapy delivery
nor in a better patient outcome.25e28 Indeed, more complica-
tions related to the atrial lead have been observed.26 Whether
the unique Biotronik device using dual chamber detection
with a single lead will provide better results, it awaits to be
proven.
As a general rule, each discrimination algorithm has to
be used at the best of its clinical performance as reported
in literature, and needs to be tailored to the individual
patient, although this is time consuming. For instance, in
the event of rate-dependent aberrancy during SVT, morpho-
logic discriminators should be reprogrammed to allow
matching the template at a lower percentage, or the template
should be collected during aberrancy, and template update
be disabled.29 No inference of the performance of an algo-
rithm (for instance, stability) can be made in a different
manufacturer device, as they work differently and with non-
comparable diagnostic pathways, as reported in the
Appendix.
These considerations are of key importance when inter-
preting the data of comparisons among manufacturers.22,24
Based on actual knowledge of Detection Duration and
Discriminators programming, the minimum target to be
achieved nowadays is fewer than 3.6% of patients receiving
inappropriate shocks.8,16e18
For the purpose of a pragmatic approach to arrhythmia
detection, Discriminators programming is reported in Table 2.
Discrimination based on hemodynamic tolerance of a fast
rhythm, whatever the chamber of origin, can be a possible
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technologies for intracardiac pressure or stroke volume
measurements are apt to work in conjunction with nowadays
ICDs as connected devices. It is speculative that such
system could be implemented in either transvenous or non-
transvenous devices.
2.6. T-wave oversensing
Double counting and delivery of inappropriate shocks due to T
wave oversensing occurs in less than 4% of transvenous ICD
patients. This is usually related to any of these situations:
- small R waves (ventricular arrhythmogenic cardiomyopa-
thy, new-onset right bundle branch block, fall of the RV
signal amplitude due to changes in the lead-tissue inter-
face, use of anti-arrhythmic drugs)
- tall or delayed T waves (hypertrophic cardiomyopathy,
long QT, post-paced T waves in CRT-D when sinus rhythm
exceeds the UTR, electrolytes imbalance).
It is usually managed by delaying the increase of ventric-
ular sensitivity towards its maximum value (St Jude Medical
and Biotronik), or by detecting the T wave with a dedicated
algorithm (Medtronic, NayaMed), or keeping the UTR as fast as
the individual maximum sinus rate in CRT-Ds to prevent the
loss of biventricular pacing. Decreasing ventricular sensitivity
should be regarded as the last resort, to minimize the risk of
ventricular undersensing during VF. Unacceptably low Rwave
signal (<1.5 mV) associated with device under-performance
usually require lead revision.
In the subcutaneous ICD, 7% of patients had inappropriate
shocks because of T-wave oversensing, that required re-
intervention in 20% of cases.23 In a young population (mean
age 20 years) inappropriate shocks due to T-wave oversensing
were 50% of totally delivered shocks.30
2.7. Non-cardiac signal detection
Signals arising from the external environment or stemming
from lead insulation defects/fractures (termed “noise”) account
for up to 4% of delivered shocks in large trials.5,31 A unique
feature of Medtronic and NayaMed can help to avoid this
threatened occurrence, by withholding VF therapy delivery for
up to 45 s when noise is detected, as “noise” is rarely observed
for longer than 20 s. Therapy delivery is resumed automatically
if “noise” persists more than 45 s. Moreover, the algorithm
automatically prolongs VF detection to 30/40 intervals to
decrease the chances of inappropriate “noise” detection; this
feature can work with leads from any manufacturer.32
2.8. Termination of ventricular arrhythmias
2.8.1. VT and FVT termination
Several studies have demonstrated that both VT slower than
200 bpm and FVT (200e250 bpm) can be safely terminated with
ATP sparing the painful and potentially harmful effect of ICD
shocks.10,18,31,33,34 This approach not only enables a superior
patient comfort, but also improves the ICD service of life, each
capacitor charge impacting about 15 days of battery longevity.Following the pilot PAINFREE study, several randomized
studies have consistently demonstrated that:
- ATP effectively terminates nearly 70% of VTs and
FVTs10,18,31
- ATP efficacy ismaintained with a long detection duration18
- Physician-tailored programming of ATP is as effective as an
empiric one, thus up-loading a pre-defined setting enables
an optimal outcome in the majority of patients31
- long ATP bursts (15 pulses) are as effective as standard (8
pulses) at no excess of acceleration or syncope, a slightly
superior efficacy being observed only in patients with an
EF> 40%, therefore cannot be recommended as first
choice33
- in CRT-D patients, Biventricular (BIV) ATP has a signifi-
cantly lower risk of arrhythmia acceleration compared to
RV-only ATP, and is more effective in patients with
ischemic heart disease34
A general approach is reported in Table 1, and can be rec-
ommended as:
- single ATP attempt for 200e250 bpm VTs. At faster rates up
to 300 bpm, ATP is unlikely to have a similar effectiveness,
however it causes no harmwhen delivered during charging
- 2 bursts and one ramp can be considered in the
170e200 bpm VT range
- more burst and ramp attempts on VT slower than 170 bpm
can be useful/needed in individual patients to achieve
tailored therapy, and as such cannot be recommended
based on randomized trials
Early VT recurrences after a successful ATP e but before
the episode is closedemay cause unnecessary shock delivery.
This pitiful event can be avoided by decreasing the intervals to
detect normal rhythm resumption from 5 (shipment) to 3 in St
Jude Medical devices. Medtronic features “Confirmationþ”
(shipment, non-programmable): VT/VF termination is detec-
ted when the cycle is longer than the average treated
arrhythmia þ60 ms. In the event of consecutive VT/VF re-
currences in a few beats, delivery of therapy 1will occur again,
thus sticking to an effective, painless, and battery-saving ATP
treatment.
2.8.2. VF termination
Shock delivery is the main therapy of true VF, defined as a
rhythm faster than 250 bpm. True VF episodes account for
about 10e15% of arrhythmia episodes recorded in ICD
patients.5,10,16
ICDs are reported to decrease sudden death mortality by
about 70%. Whereas many events can cause sudden death,
unresponsiveness to defibrillation is the cause in probably
about 5% of patients nowadays.35e37 In recent years significant
improvements have occurred in ICD technology, enabling
delivery of about 35J in a reliably short charging time and
programmability of the shocking pathway, such that shock
failure should be viewed more as a patient-related issue than
as a device issue. Indeed, the probabilistic nature of defibril-
lation is such that success is highly dependent on the clinical
situation at the time of arrhythmia occurrence, with heart
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key role in the appraisal of shock failure. Changing the
shocking pathway allows greater possibilities of arrhythmia
termination, owing to the probabilistic nature of the defibril-
lation process, hence reversal of the shocking pathway should
occur at some point in the sequence of charges delivered for a
single VF episode (Fig. 3). The SQICD reverses shocking
pathway automatically after a delivered charge failure, and
keeps the successful pathway as the first therapy to be
delivered in a newer arrhythmia episode.
Although several studies have reported a similar success
rate whether an only minimal safety margin is used as
opposed to a full energy shock, it has become common prac-
tice to program a full charge first shock after a long detection
duration, owing to the short and reliably stable capacitor
charging time across the full span of ICD life service.38
The choice of a dual vs a single coil shocking lead is largely
debated, since no trial has ever been conducted to solve any of
the controversial issues still pending after 20 years of trans-
venous ICD therapy. In favor of dual-coil leads stands a lower
energy requirement to terminate induced VF, that is not
supported by any trial in terms of survival benefit. In favor of
single coil leads stands a perceived benefit for lead extraction,
that is not supported by any trial reporting fewer complica-
tions during lead extraction. Indeed, the predictors of both
lead extraction failure and catastrophic complications are
older age of lead in service and infection as cause of lead
extraction regardless of lead type (pacemaker or ICD), and use
of powered sheaths.39
As a general approach, dual-coil leads can be recom-
mended in patients at risk of a high defibrillation threshold
such as hypertrophic cardiomyopathy, ventricular arrhyth-
mogenic cardiomyopathy, operated Tetralogy of Fallot with
severe ventricular enlargement. Primary ion channel disease
patients (Brugada for instance) are occasionally found to have
higher than average defibrillation thresholds.
2.9. Monitor zone programming
Programming amonitoring zonemay be helpful to investigate
patients with symptoms, or to detect asymptomatic AF that
has clinical relevance for stroke management.40,41 In our
practice we program a Monitor zone from 140 to the VT/VF
cut-off rate: Discriminators are active to help the diagnostic
process (Fig. 2).
2.10. Device and clinical alerts
Device alerts on battery longevity and lead integrity issues are
on by shipment. In the view of the widespread adoption of
remote device and patient monitoring, automatic alerts
should also be used to enable a prompt response to changing
medical conditions. Beyond fast NSVT,11 this is particularly
important for and AF, where stroke prevention and rate/
rhythm control strategies are concerned, and for heart failure
management.40e46 Composite heart failure scores based on
the clinical profile and on device data are built to predict
clinical worsening and hospitalization risk, and as such are
made available to clinicians. Moreover, when alerts are auto-
matically issued to the device clinic and/or the referringphysician, clinical decisions are made in the appropriate time
frame to prevent untoward events, thereby decreasing in-
hospital clinical visits.47 This appears to translate also in a
significant all-cause and cardiovascular mortality benefit in
heart failure patients, as from the preliminary data disclosure
of the IN-TIME trial.482.11. Choice of the device type
Based on available studies, no advantage has been observed
in the use of Dual Chamber vs Single Chamber ICDs,
although the former enable a more appropriate arrhythmia
detection and superior detection of AF occurrence and AF
burden.25e28 Dual chamber devices should be nowadays
preferred in a minority of patients, when cardiac stimulation
is needed in the setting of a normal left ventricular systolic
function. The availability of a single chamber ICD capable of
dual-chamber detection could possibly further decrease the
use of dual chamber devices.20 SQICD fit into this trend to-
wards single chamber devices, and their reliability is already
very close to transvenous ICDs, although the rate of inap-
propriate shock delivery (13% patients)23 is still unacceptable
compared to actual transvenous ICD (2.4e3.6%
patients).8,16e18 However, some unmet needs still prevent the
broad adoption of the SQICD in the general ICD population:
lack of ATP, bulky big size that poses skin issues in young or
thin habit patients, subcutaneous lead infections, cost (twice
a single chamber ICD), and limited device longevity (5 years)
compared to the past generation transvenous units (close to
or >10 years).23,30,49,50 Its usage is actually appropriate for a
minority of patients with lead infection who need a fast re-
implantation, or when a venous access issue is the key
point to be managed.3. Conclusions
ICDprogrammingcanbemade safe andeffective inpreventing
inappropriate therapy delivery (fewer than 3% of patients), by
implementing a custom-made programming stemming from
evidence by clinical trials, that can be applied to the broad ICD/
CRT-D population and used for tailoring individualized ther-
apy. Such settings can be uploaded from the programmer to
increase efficiency andminimize the risk of random errors.AppendixSVT discrimination
Algorithms functioning across different manufacturers.
Onset is intended to rule out sinus tachycardia because of
its gradual rate acceleration. Failure to detect VT/VF because
of onset may occur when the arrhythmia occurs during sinus
tachycardia or it is triggered by an ongoing SVT or atrial
fibrillation (AF). It has to be remembered that onset works
differently across manufacturers:
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counter to reach detection, thus overrules all other dis-
criminators. Arrhythmia detection cannot occur if onset
misclassifies VT;
- in St Jude Medical devices, onset works at Detection as
part of the detection logic, together with stability and
Morphology Discrimination in single chamber ICDs;
- in Boston Scientific devices onset and stability cannot work
together with the morphologic discriminator (Rhythm ID).
Onset and stability work together in single chamber ICDs,
each overruling the other in favor of sensitivity for VT;
- in Biotronik devices a single chamber, single-lead device
can provide dual chamber detection owing to a highly
reliable P wave sensing.19 Its decisional tree makes mini-
mal use of onset20;
- in Sorin devices onset is applied sequentially to rule out
sinus tachycardia only after stability has detected a fast
regular rhythm.
In general, Onset is of little use, unless coupled to stability
or other discriminators as in St Jude Medical devices.
Stability is intended to rule out Atrial Arrhythmias with
irregular atrio-ventricular conduction. Failure of Stability may
occurwith SVTs and highly regular AF at fast ventricular rates,
that mimic the spontaneous cycle length variability of VT
(10e40 ms).
As Onset, Stability works differently acrossmanufacturers:
- in Medtronic/NayaMed devices stability works as soon as
VT counter reaches 3, and resets the VT counter to 0 when
at least 1 interval in a window of 4 differs more than the
programmed stability value; arrhythmia detection can
thus be indefinitely delayed until a regular rhythm de-
velops (VT) or the probabilistic VF counter is filled. Stability
can work after therapy delivery during re-detection;
- in St Jude Medical devices stability is part of the detection
logic, and is applied once the detection time has elapsed,
together with onset and Morphology Discrimination. Sta-
bility compares the difference of the 2nd shortest and
longest intervals of a programmable sampling window
(8e20 intervals) to a defined programmable value, and de-
clares SVT when the former exceeds the latter;
- in Boston Scientific devices onset and stability cannot work
together with the morphologic discriminator (Rhythm ID).
Stability and onset override each other in favor of VT
diagnosis. Intervals entering the detection rate are
compared to the variability of the last 5 beats: the weighted
average is then calculated to be compared with the pro-
grammed stability. Stability can be used during re-
detection after therapy delivery;
- in Biotronik devices a single lead device can provide dual
chamber detection, whose decisional treemakes extensive
use of stability in both scenarios of atrial rate equal or
faster than ventricular rate. Stability is a programmable
percentage of cycle length in single chamber devices, or an
absolute programmable value in dual chamber. Each beat
is weighted differently depending on the specific scenario
of the decisional tree19,20;
- in Sorin devices, stability is the first step in the discrimi-
nation pathway. Sophisticated computation of longintervals e though sporadic e is used to unmask regular
AF. Arrhythmias with a regular interval are further
analyzed by onset to rule out sinus tachycardia;
- In the subcutaneous ICD, interval stability is part of the
Conditional Shock Zone detection process, together with 3
other algorithms that work to avoid sensing the T wave,
and check for changes in the QRSwidth andQRS amplitude
to confirm VT.Morphologic discriminators
They work by comparing the EGM of the rhythm entering the
VT zone (VF also for Medtronic and NayaMed) with a reference
template that is acquired during the patient’s normal rhythm,
and is periodically, automatically updated. None of these
discriminators can be used after therapy has been delivered,
because the residual voltage (polarization) on the coil causes
marked changes (widening, polarity change) to the EGM being
recorded, making the comparison with the template unreli-
able. There are marked differences across manufacturers:
- Wavelet is used in Medtronic and NayaMed devices. The
template is collected from the can to RV Coil EGM; it is
automatically updated, but the amplitude range needs to
be manually programmed to avoid signal clipping. VT is
declared when 6 of the 8 beats before detection do not
match with the template. The percentage of match with
the template is programmable; shipment is 70% and re-
ported to be optimal in the majority of cases, but reprog-
ramming is needed in specific cases (less than 5% in my
experience). From the Protecta release onward, Wavelet
has been added to dual chamber discrimination on top of
PR Logic;
- Morphology Discrimination is used in St Jude Medical de-
vices. Template was collected tip to ring in former releases,
whereas it is available either from can to RV coil or tip to
ring in the Ellipse release. The amplitude range is auto-
matically set. In the old tip to ring releases VT is declared
when 6 of the 12 beats before detection do not match the
template. The percentage of match with the template is
programmable; shipment is 60% and reported to be optimal
in themajority of cases, but reprogramming was needed in
the tip to ring only releases (10% of patients in my experi-
ence). With can to RV coil, VT is diagnosed when 8/10 in-
tervals do not match; shipment matching percentage is
90%: both parameters are programmable. It has to be
remembered that when all discriminators are turned ON, a
logic as ANY, 2/3, or ALL needs to be defined for detection to
occur: 2/3 has the best sensitivity/specificity ratio,
although a single report found no difference compared to
Morphology alone21;
- Rhythm ID is used in Boston Scientific devices. It uses
alignment of the can to coil EGM (eight points) to the Rate
EGM to build the reference template. When alignment of
the former is lost during a fast rhythm, non-match is
detected. VT is declared when 8 of 10 beats match below
94% with the template. It used to be a non-programmable
algorithm until the Incepta release, where match per-
centage is programmable: lowering the matching
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ficity for SVT detection;
- Signal analysis is operated in the subcutaneous ICD in the
“Conditional Shock zone” to confirm VT, based on changes
of QRS width and amplitude. This zone should always be
used, up to 240 bpm.
Atrial Rhythm analysis in dual chamber devices
The discrimination of SVTs from VT (VF also for Medtronic
and NayaMed) is based on the relationship of atrial and ven-
tricular EGMs. The functioning of combined chamber analysis
is markedly different across manufacturers:
- in Medtronic and NayaMed the algorithm named PR Logic
consecutively classify beats relying on patterns that are
based on the relative timing of the atrial EGM respect to the
ventricular interval. By this way each beat is labeled as VT,
VF, Sinus Tachycardia, SVT, Atrial Tachycardia, or Atrial
Fibrillation. Detection of far-field R wave sensing is pro-
vided, and is part of the correct pattern identification. From
the Protecta release onwards, wavelet has been added on
top of PR Logic.
- In St Jude Medical, Boston Scientific and Biotronik the
relationship of atrial and ventricular rate is used for a rate
branch analysis, where V rate > A rate qualifies VT, hence
no other discrimination is applied. On the contrary, both
V ¼ A and V < A rate are managed stepwise by further
discrimination with Morphologic discriminators, Stability,
and Onset (not used in Boston, applied in a single scenario
in Biotronik). Whereas in Boston Scientific and Biotronik
these added algorithms work stepwise sequentially, in ST
Jude Medical the discriminators work in pair with a pro-
grammable ANY or ALL logic in the 2 different settings:
Onset and Morphology for V ¼ A, Stability and Morphology
for V < A.
- In Sorin devices, stability is the entry discriminator to
detect AF. Atrial to ventricular relationship is used for
arrhythmia discrimination in the presence of a regular
rhythm with an N:1 relationship to rule out VT. Onset is
used in the setting of a 1:1 atrioventricular relationship,
where sinus tachycardia is to be discriminated from VT
with retrograde conduction. Chamber of origin is used to
help discrimination of arrhythmias with sudden onset.Conflicts of interest
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